Home Healthcare IT Ear Cancer Treatment Market Share, Strategy, Growth - Industry Outlook, 2027

Ear Cancer Treatment Market

Ear Cancer Treatment Market Size, Share & Trends Analysis Report By Therapy (Chemotherapy, Immunotherapy, Surgical Therapy, Radiation therapy, Others), By End-Users (Hospitals and clinics, Retail Pharmacies, E-commerce platforms, Cancer research institute, others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI571DR
Study Period 2020-2032 CAGR 4.7%
Historical Period 2020-2022 Forecast Period 2024-2032
Base Year 2023 Base Year Market Size USD XX Billion
Forecast Year 2032 Forecast Year Market Size USD XX Billion
Largest Market North America Fastest Growing Market Asia Pacific
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

Ear cancer often starts as skin cancer on the outer ear and then spreads throughout the various ear structures, including the ear canal and eardrum. The treatment for ear cancer depends on the stages of cancer, the size of the tumor, and its location. Ear cancer is extremely rare. In the U.S., only about 300 people are diagnosed with ear cancer every year, as per the National Cancer Institute. Moreover, the oncologist prefers surgery as a first-line treatment option for ear cancer and performs tumor removal procedure either by radiation therapy or chemotherapy based on the severity of the ear cancer. When cancer occurs on an ear, the size of the ear may be reduced owing to the surgical removal of cancer, which can be resurrected using a 3D bioprinting technology, as developed by Dassault Systems. In most cases, it is observed that ear cancer is caused by frequent ear infections and prolonged exposure to solar radiation. Fair-skinned people are at more risk of developing outer ear cancer.

Certain types of ear cancer are more common in the geriatric population. For instance, as per the study of the national health institute, geriatrics are more likely to develop squamous cell carcinoma of the temporal bone. One such type of ear cancer is Adenoid cystic carcinoma, which primarily develops on the external ear canal and tends to invade local tissue and ear cartilage aggressively. Similarly, Parotid carcinoma, a cancer of salivary glands, is also responsible for causing inner ear malignancy. The inner or middle ear cancer diagnosis may be difficult to carry out and many physicians rely on imaging techniques like MRI or CT scans.

Market Dynamics

Market Drivers

In the last few years, cancer treatment has been progressing at a significant rate and is providing noticeable improvements in the therapeutic benefits to cancer patients, which in the near future will significantly boost the ear cancer market. The development in the therapeutic technology, new drugs pipeline, related clinical trial activity, and the increasing number of approved cancer therapies is subsequently boosting the market growth. Moreover, global spending on cancer treatment and medicines is projected to increase at a significant pace due to the growing global support and therapeutic care, which is further driving the ear cancer treatment market. Following are the important factors driving the market for Ear cancer treatments:

Small Patient Pool

Current trends in drug pipelines suggest that cancers with lower incidence will account for almost about 50% of the sales by 2025, meaning that the manufacturers are shifting towards specialized cancers, such as ear cancer, head and neck cancers, esophageal cancer and others with greater unmet medical needs. Nearly half of the clinical trial is conducted by some of the top oncological players. The move toward such a narrower patient pool has important implications like easier market access and easy patient identification. Ear cancer, particularly Basal cell carcinoma of the outer ear, is more common in the geriatric population with white skin. As per the WHO, globally, the geriatric population is estimated to reach 2 billion by 2050 from 900 million in 2015. Some of the factors driving the ear cancer treatment market include the surge in the geriatric population, rising ear cancer awareness, and favorable reimbursement scenario. As per estimates of the Union for International Cancer Control (UICC), about 5% of squamous cell carcinomas of the head and neck affect either outer ear or inner ear. Some of the carcinomas of secretary glands like Adenoid cystic carcinoma of salivary gland affect the middle and inner ear causing severe hearing loss and blood discharge from the ear. The cancer is very much rare. In the U.S., only about 1200 patients have been diagnosed with Adenoid cystic carcinoma and very few of them are suffering from ear cancer. Similarly, adenoid cystic carcinoma of the ear has a global incidence of 3 to 4 cases per million per year.

Increased Consumption of Alcohol, Tobacco and Smoking Habits

The risk of ear cancer increases with increasing alcohol consumption, chewing tobacco, and smoking. Chewing tobacco results in cancer of the salivary glands, which may spread to the middle and inner ear causing severe hearing loss and tinnitus. As per the National Institute on Alcohol Abuse and Alcoholism, in 2015, around 26.9% of people aged 18 and above were found to be alcoholic and many of them were suffering from either cancer or liver ailments. Similarly, 8 out of 10 oral cancer patients were found to be smokers. In the U.S., over 50,000 cases of oral cancers induced due to smoking were diagnosed each year. Globally, there are around 1.25 billion smokers and more than one million people die of tobacco-induced oral cancer each year.

Rise in Environmental Pollution, Radiation Exposure, and Genetic Factors

Exposure of ultraviolet radiation is considered as a major cause of ear melanoma, which can be attributed to the rapid depletion of the ozone layer. Some of the factors driving the market growth include the prolonged exposure to the solar radiation, fair complexion, continuous exposure to chemical carcinogens, such as arsenic, asbestos and certain mutagenic factors elevate the risk of developing squamous cell carcinoma in the ear canal. Such environmental factors increase the prevalence rate of ear canal squamous cell carcinoma, in particular among Caucasians, which is further driving the global market for ear cancer treatment.

Advances in Technologies and R&D Activities in Cancer Treatment

Technological developments, such as developments of new targeted molecules through gene therapy, monoclonal antibodies, and antibody-drug conjugates, entry of biosimilar in the market, 3D bioprinting of ear, and autoplastic ear reconstruction are likely to drive the market growth in the years to come. Additionally, the development of novel treatment and favorable reimbursement scenarios along with the collaboration of pharmaceutical and biotech companies to improve access to cancer care in low and middle-income countries is driving the market growth.

Regional Analysis

North America to Dominate the Ear Cancer Treatment Market

North America is dominating the ear cancer treatment market and will continue the same during the forecast period. This can be attributed to the growing incidences of ear infections and skin cancers in the geriatric population, rising awareness of advanced treatments, and favorable reimbursement scenarios for cancer treatments. As per the American Academy of Dermatology, in the U.S., around 10,000 people are diagnosed with skin-related malignancies every day, out of which, about 3% are diagnosed with ear cancers. Thus, rising cases of ear cartilage malignancies are expected to propel the market growth to some extent. In addition to this, the government of the U.S. is actively supporting and increasing funding towards cancer treatment, which is further creating umpteen opportunities for the ear cancer treatment market. For instance, in 2017, the U.S National Cancer Institute (NCI) spent about USD 5,600 million in cancer research and treatment.

According to the article published in the journal Deutsches Arztteblatt international, around 100 cases of Basal cell carcinoma of the outer ear is reported in Great Britain annually, and around 70 to 80 cases are reported in Germany, Switzerland, and Italy. Some of the factors driving the market include the increasing awareness regarding ear cancer, technological advancements, the high adoption rate of newer therapeutics, and rising skilled and specialist medical professionals across Europe.

Asia-Pacific is providing lucrative growth opportunities for key players operating in the ear cancer treatment market as the region is housing a huge population base, increased incidence of outer and inner ear infections, and increased demand for combination ear cancer therapy. This can be attributed to rising alcohol consumption, increasing smoking activities, and higher usage of tobacco in the region. To attend to the situation, the governments in the region are actively working to develop umpteen programs, camps, and initiatives for improving cancer care facilities in the region. For instance, the government of India approved the establishment of State Cancer Institutes and Tertiary Care Cancer Centers in the country, which is expected to boost the regional market to a certain extent.

In South America, the increasing alcohol and smoking habits and lack of awareness regarding ear cancer complications are driving the market growth. For instance, around 1.6 million people are living with undiagnosed cancer in the region. To address the dire situation, South American countries have taken various measures into consideration to improve healthcare coverage. For instance, Brazil, Argentina, and Colombia are providing universal health coverage, which can be attributed to the increasing access to healthcare services, reducing inequalities, and increasing public spending on healthcare.

The Middle East & Africa are expected to exhibit a slow growth in the ear cancer treatment market due to poor access to healthcare, limited technical infrastructure, and low quality of cancer diagnostics. In the Middle East, the UAE is expected to hold the largest share in the market owing to the development in the healthcare sector and the rising availability of specialty care centers. On the other hand, Africa holds the least share in the market due to low spending power, poor healthcare infrastructure, and limited availability of funds in the region.

Report Scope

Report Metric Details
By Therapy
  1. Chemotherapy
    1. Systemic
    2. targeted
  2. Immunotherapy
  3. Surgical Therapy
    1. Photodynamic therapy
    2. Cryotherapy
    3. Mohs micrographic surgery
  4. Radiation therapy
  5. Others
By End-Users
  1. Hospitals and clinics
  2. Retail Pharmacies
  3. E-commerce platforms
  4. Cancer research institute
  5. others
Company Profiles Bristol-Myers Squibb (BMS) Oncology Venture Merck and Company Inc. F.Hoffmann-La Roche Amgen Inc. Celgene Corporation Sun Pharmaceutical AbbVie Novartis Regeneron Pharmaceuticals AstraZeneca Eli Lilly GlaxoSmithKline plc Teva Pharmaceutical Industries Ltd.
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

Surgical Therapies for Ear Cancer is Expected to Be the Fastest-Growing Segment

The ear cancer treatment market share is segmented on the basis of therapy and end-users. By therapy, the market is segmented into chemotherapy, immunotherapy, surgical therapy, radiation therapy, and others. Based on end-users, the market is further divided into hospitals and clinics, retail pharmacies, e-commerce platforms, cancer research institute, and others.

Surgery is the most preferred treatment option for the treatment of ear cancer and hence will dominate the ear cancer treatment market. It is considered the first-line curative approach, which includes photodynamic surgery, cryosurgery, and Mohs micrographic surgery. The photodynamic surgery includes a drug or photosensitizing agent, which is exposed to a specific wavelength of light, producing conjugate of oxygen that kills malignant cancer cells. The cryosurgery uses an extreme cold environment from liquid nitrogen to destroy cancerous outgrowth on the ear. Lastly, Moh’s micrographic surgery involves the precise removal of cancer tissue without harming healthy skin cells. It is also considered as cost-effective as other surgical methods for the treatment of ear cancer. Surgical therapy has been considered as more efficient due to its lowest possible recurrence and maximum cure rates for basal cell carcinoma of the ear, leading to its high demand, which is further driving the segment growth.

New Age of Combination Therapy

The other standard treatment options for ear cancer include chemotherapy, immunotherapy, and radiation therapy. The chemotherapy segment accounted for the largest share of the ear cancer treatment market. This can be attributed to the increasing usage of chemotherapeutic drugs and the rising benefits of combination therapy. Currently, drugs such as bleomycin, cetuximab, docetaxel, paclitaxel, capecitabine, hydroxyurea, methotrexate, docetaxel, 5-fluorouracil, and methotrexate are approved for the treatment of ear cancer. However, chemotherapeutic agents are cytotoxic that harm malignant as well as healthy cells in cancer patients, which is further restraining the market growth to some extent.

Based on positive clinical outcomes, immunotherapies have gained huge popularity as a precision medicine initiative for the treatment of ear cancer and the demand for immunotherapy is expected to rise during the forecast period. This can be accredited to the increasing use of targeted immune therapies and a strong presence of pipeline drugs. For instance, Pembrolizumab (Keytruda) developed by Merck & Company and Nivolumab (Opdivo) developed by Bristol-Myers Squibb is approved by the U.S. FDA for the treatment of recurrent or metastatic ear squamous cell carcinoma.

Targeted immune therapy is expected to grow at a lucrative CAGR as it offers umpteen benefits, including limited adverse effects and higher efficiency of targeted immune therapy drugs. Advancements in gene therapies have led to the development of targeted cancer therapies for the treatment of patients who are incurable by intensive cytotoxic chemotherapy.

The radiation therapy segment is expected to witness steady growth over the forecast period owing to the increasing number of advanced ear melanoma cases and the use of radiation as an adjuvant therapy post-surgery. Radiation therapy is rarely used as primary treatment and only administered to patients in later malignancy stages, who cannot be treated with surgery.

End-User Insights

As predicted by industry experts, the hospital segment will hold the largest market share owing to the frequent visits of patients and a center of primary care that enables them to treat ear carcinoma for a wide range of the population. It is also projected that cancer research institutes will continue the trend for ear cancer research owing to increases capability of specialized treatment for ear cancer, which is facilitated by various private and public funding organizations.

Market Size By Therapy

Recent Developments

  • In December 2016: Sun Pharmaceutical acquired Novartis 'branded oncology product, named Odomzo’ at USD 175 million
  • In July 2016: Bristol-Myers Squibb acquired Cormorant Pharmaceuticals to expand its immuno-oncology pipeline
  • Regeneron Pharmaceuticals, Inc. recently got approval for ‘Libtayo’ (cemiplimab-rwlc), a monoclonal antibody drug indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma of the outer ear
  • Roche and Bausch Health have the highest number of completed clinical trials for basal cell carcinoma of the ear

Top Key Players

Bristol-Myers Squibb (BMS) Oncology Venture Merck and Company Inc. F.Hoffmann-La Roche Amgen Inc. Celgene Corporation Sun Pharmaceutical AbbVie Novartis Regeneron Pharmaceuticals AstraZeneca Eli Lilly GlaxoSmithKline plc Teva Pharmaceutical Industries Ltd. Others

Frequently Asked Questions (FAQs)

What is the estimated growth rate (CAGR) of the Ear Cancer Treatment Market?
Ear Cancer Treatment Market size will grow at approx. CAGR of 4.7% during the forecast period.
Some of the top prominent players in Ear Cancer Treatment Market are, Bristol-Myers Squibb (BMS), Oncology Venture, Merck and Company Inc., F.Hoffmann-La Roche, Amgen Inc., Celgene Corporation, Sun Pharmaceutical, AbbVie, Novartis, Regeneron Pharmaceuticals, AstraZeneca, Eli Lilly, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., etc.
North America has held a dominant position in the Ear Cancer Treatment Market, with the largest market share.
The Asia Pacific region is projected to exhibit the highest rate of growth in the Ear Cancer Treatment Market.
The global Ear Cancer Treatment Market report is segmented as follows: By Therapy, By End-Users

We are featured on :